Furthermore, due to enhanced CD8+ T cell response and IFN-γ secretion, this nanovaccine retarded the tumor-occurring time, suppressed the tumor growth, and inhibited the tumor metastasis in all prophylactic, therapeutic, and metastatic melanoma models. The gene discussed is CD8A; the disease is neoplasm.